Zylox-Tonbridge Details Valuation Basis for Remaining Stake in Vascular Device Platform

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has issued an update.

Zylox-Tonbridge Medical Technology has detailed the valuation basis for its staged acquisition of the remaining equity in a European vascular device maker, after exercising an option to buy an additional 11% stake in March 2026. The company expects this platform to bolster its overseas vascular business through control of brand, intellectual property and distribution, as well as closer integration with its existing sales network.

The consideration for the 11% stake was set after arm’s length talks, referencing the target’s improving financials, including a sharp narrowing of net loss in 2025 and a solid capital position, alongside its advanced positioning in the global peripheral venous stenting market. Pricing for the further acquisition planned for the first half of 2028 also reflects anticipated growth in market coverage, an expanded product portfolio and R&D-driven synergies, including at least 10 new or upgraded products over three years.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. is a China-based medical technology company focused on vascular interventional devices, with a particular emphasis on peripheral venous stenting products. The group uses the target company as its overseas vascular products platform, leveraging its comprehensive portfolio and strong global brand to expand international market reach and strengthen its sales and distribution network.

Average Trading Volume: 733,965

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.63B

See more insights into 2190 stock on TipRanks’ Stock Analysis page.